Coffee is consistently linked to lower liver cirrhosis and cancer risk — in weak studies

Higher coffee consumption is consistently associated with lower rates of the two most serious liver conditions — cirrhosis and liver cancer — with an extra two cups a day linked to roughly a third lower risk of each [s1] [s2]. The catch, and it is a real one, is that every study behind these numbers is observational, and the overall quality of evidence is graded very low, so the data show a strong association without proving coffee is the cause [s1].

The liver cancer evidence

A systematic review and dose-response meta-analysis in BMJ Open examined coffee and hepatocellular carcinoma, the main form of liver cancer [s1]. It pooled 18 cohort studies covering 2,272,642 participants and 2,905 cases, plus eight case-control studies [s1]. An extra two cups of coffee a day was associated with a 35% reduction in the risk of liver cancer (relative risk 0.65, 95% confidence interval 0.59 to 0.72) [s1].

Two details make the finding harder to dismiss as pure confounding. First, decaffeinated coffee also showed a reduction, if a smaller one: an extra two cups of caffeinated coffee was associated with a 27% lower risk (RR 0.73, 0.63 to 0.85), and decaffeinated with a 14% lower risk (RR 0.86, 0.74 to 1.00) [s1]. That the decaf effect exists at all suggests something other than caffeine may be involved. Second, the association was not significantly changed by the stage of liver disease, or by high alcohol consumption, high body mass index, type 2 diabetes, smoking, or hepatitis B and C — the usual suspects you would expect to explain it away [s1].

The finding also held up across study designs, which is reassuring because case-control studies are more prone to certain biases than prospective cohorts. Pooling only the higher-quality cohort studies still yielded a 29% reduction (RR 0.71, 0.65 to 0.77), while the case-control studies showed a larger 47% reduction (RR 0.53, 0.41 to 0.69) [s1]. The direction was the same either way; the cohort estimate is the more conservative and the more trustworthy of the two.

The cirrhosis evidence

A separate meta-analysis in Alimentary Pharmacology & Therapeutics looked at coffee and cirrhosis, pooling five cohort and four case-control studies involving 1,990 cases among 432,133 participants [s2]. A daily increase of two cups of coffee was associated with a pooled relative risk of cirrhosis of 0.56 (95% CI 0.44 to 0.68) — again, a roughly halved risk with a clear dose-response [s2]. As with the cancer analysis, the effect appeared in both study designs, with a pooled relative risk of 0.58 from cohort studies and 0.52 from case-control studies [s2]. The association held for alcoholic cirrhosis specifically (RR 0.62, 0.51 to 0.73) and for death from cirrhosis (RR 0.55, 0.35 to 0.74) [s2]. The consistency across cirrhosis and cancer, two related but distinct liver outcomes, is part of what makes researchers reluctant to write the pattern off entirely.

Why the caveat is not boilerplate

The consistency across two liver conditions, a dose-response gradient, and robustness to obvious confounders are the features that make researchers take an observational signal seriously. But the BMJ Open authors themselves graded the quality of evidence as "very low" under the GRADE system, citing the lack of randomised trials, potential publication bias, and the fact that there is not even an agreed definition of what counts as a "cup" of coffee [s1]. Observational studies also cannot rule out reverse causation — people with early liver trouble may cut back on coffee — or the possibility that coffee drinkers differ in unmeasured ways.

What this leaves a reader with

The honest summary is a genuinely encouraging association that stops short of a recommendation: across large populations, more coffee tracks with less cirrhosis and less liver cancer, even for decaf, but no trial has shown that drinking coffee causes that protection [s1] [s2]. That is a different statement from "coffee protects your liver," and the gap between them is exactly what the very-low evidence grade is flagging. Coffee also affects sleep, anxiety and heart rhythm in ways that vary by person, so it is not a liver intervention to be adopted on these numbers alone.

This article is informational and is not medical advice.

Sources

• Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis — BMJ Open, 2017-05-09
• Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis — Alimentary Pharmacology & Therapeutics, 2016-01-25